Introduction
============

Community-acquired pneumonia (CAP) is recognized as the second-most common reason for hospitalization and a leading cause of morbidity and mortality that tends to disproportionately affect older (≥65 years) adults.[@b1-tcrm-10-189] Indeed, older patients are at particularly high risk for CAP, due to the clustering of multiple comorbid chronic conditions, and each year in the US there are approximately 900,000 episodes of CAP, with approximately 40% requiring hospitalization, and close to 50,000 pneumonia-related deaths.[@b2-tcrm-10-189],[@b3-tcrm-10-189]

It is increasingly recognized that the acute management of many diseases, including CAP, results in numerous medication changes during transitions of care.[@b4-tcrm-10-189] Studies have shown that although often deliberate, many unintended medication discrepancies occur at the time of admission and are often carried through to discharge.[@b5-tcrm-10-189] Moreover, medications are frequently initiated and may or may not be intentionally prescribed at discharge.[@b6-tcrm-10-189] The impact of unintentional discontinuation of medications and new starts during transitions of care include adverse effects, drug interactions, rehospitalization, and other effects of under- or overtreatment.[@b6-tcrm-10-189]--[@b10-tcrm-10-189]

Furthermore, the potential impact of medication changes during transition of care may be more pronounced in older patients due to the use of multiple medications, or polypharmacy. Indeed, approximately a third of older adults in the US use five or more prescription medications concurrently, with some reports suggesting rates as high as 40%--80% among those 65 years and older.[@b11-tcrm-10-189]--[@b16-tcrm-10-189] Importantly, polypharmacy is associated with an increased risk of frailty, disability, falls, poor adherence, hospitalization, drug--drug interactions, adverse drug events, and mortality.[@b4-tcrm-10-189],[@b15-tcrm-10-189],[@b17-tcrm-10-189]--[@b21-tcrm-10-189]

Identifying populations at risk of suboptimal medication use and at high risk of adverse drug events is important for understanding who and when to target those individuals' medication profiles for optimization of drug therapies. Because CAP is so common, particularly in older patients who are already subject to polypharmacy, this represents a population at particularly high risk of potentially preventable adverse drug events. Therefore, we aimed to describe transitions and patterns of medication use before and 1 year after an episode of CAP among older patients.

Materials and methods
=====================

Subjects and setting
--------------------

For 2 years (2000--2002), all patients over 17 years of age with CAP admitted to all six hospitals or presenting to any of the seven emergency departments in Edmonton, Alberta, Canada were enrolled in a population-based clinical registry. These six hospitals and one freestanding emergency department serve a population of approximately 1 million people, whereby all services are covered under a universal health care insurance plan. Details of the population-based clinical registry and prospective data-collection methods have been previously described for both inpatient and outpatient cohorts.[@b22-tcrm-10-189],[@b23-tcrm-10-189] Briefly, a standardized and previously validated clinical CAP-management pathway was implemented for all patients presenting to the hospital or emergency department with two or more signs or symptoms of CAP (productive or nonproductive cough, pleuritic chest pain, shortness of breath, temperature \>38°C, crackles on auscultation) and radiographic evidence of pneumonia. Patients were excluded if they had tuberculosis or cystic fibrosis, were immunocompromised, or were pregnant.

Trained research nurses prospectively collected data using standardized abstraction forms recording demographic data, detailed physician-confirmed clinical data, and self-reported prescription medication use within the week prior to admission (verified by health professionals and research nurses and as documented within the medical chart). In addition, a validated measure of disease-specific severity, the pneumonia severity index, was collected.[@b24-tcrm-10-189] Long-term follow-up of prescription-drug data was acquired from the administrative drug databases of Alberta Blue Cross and based on previously validated claims data,[@b25-tcrm-10-189] with data linkage obtained through deidentified unique personal health care numbers.[@b23-tcrm-10-189],[@b26-tcrm-10-189] This study was approved by the research ethics board at the University of Alberta.

Study sample
------------

We restricted our study sample to subjects aged 65 years and older, because this is a population at particularly high risk of adverse drug events[@b27-tcrm-10-189] and because prescription medication use is captured for all patients 65 years and older within the province. Furthermore, we excluded subjects that died in hospital or within 1 year postdischarge from the hospital or emergency department to allow for the full characterization of medication use following CAP treatment. Therefore, all subjects were followed for a minimum of 365 days following discharge and were alive to receive postdischarge prescriptions.

Medication-related definitions and outcomes
-------------------------------------------

We defined polypharmacy as the concurrent use of five or more medications. This definition of polypharmacy has been used in numerous other publications,[@b4-tcrm-10-189],[@b16-tcrm-10-189]--[@b18-tcrm-10-189] and has been shown to be associated with several important adverse events in older adults.[@b18-tcrm-10-189] We measured polypharmacy and medication use at baseline (1 week prior to CAP episode) and then in 90-day intervals (0--90 days', 91--180 days', 181--270 days', and 271--365 days' follow-up) for 1 year following a patient's initial CAP episode during the study period. To test the sensitivity of our results to our cutoff point of five or more medications used to define polypharmacy, we varied our definition to include the concurrent use of seven or more and ten or more unique medications.

Statistical analysis
--------------------

Baseline characteristics of the study sample are described using means and standard deviation (SD) or numbers and proportions where appropriate. We measured the number and percentage (compared to baseline) of subjects starting and stopping medications within the most prevalent therapeutic classes. In an effort to avoid difficult-to-interpret and unwieldy comparisons and descriptions, we focused our analysis on describing trends over time for only the most common therapeutic classes, defined as Anatomical Therapeutic Chemical classification system level 1 groups[@b28-tcrm-10-189] with \>20% prevalence at baseline. Analyses were further stratified by age-group (65--74, 75--84, and 85 years and older). We used generalized estimating equations to account for repeated measures and the longitudinal structure of our data. We assumed an exchangeable correlation structure. We specifically tested for changes in medication use over time using an ordinal dummy variable for each period (baseline as reference period) as our independent variable. We considered a 10% absolute change between time periods to indicate a clinically meaningful difference in drug use over time. All analyses were conducted using Stata/SE version 11.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Subject characteristics
-----------------------

There were 3,187 older patients with CAP who were either hospitalized (2,128 \[67%\]) or seen in an emergency department (1,059 \[33%\]) during our study. We excluded 143 (\<5%) without linkable follow-up data, 278 (9%) who died in hospital, and 661 (21%) who died within 1 year of discharge. Of the 2,105 subjects included in our final study sample, the mean age was 78 (SD 8) years, 50% were female, and 62% were admitted to the hospital ([Table 1](#t1-tcrm-10-189){ref-type="table"}). Most (91%) subjects were independently mobile. The most common comorbidities were cardiovascular disease (includes myocardial infarction, coronary disease, heart failure, and peripheral vascular disease), chronic obstructive pulmonary disease, mental illness, stroke, cancer, and chronic kidney disease. Fifty-eight percent of subjects were classified as having severe pneumonia based on the pneumonia severity index (class IV and V).

Medication use at baseline
--------------------------

The mean number of medications used was 4.5 (SD 2.8), with 45% of the cohort using five or more medications at baseline. The most common medication classes (as defined by the Anatomical Therapeutic Chemical classification system) with a prevalence greater than 20% used at baseline were cardiovascular agents (n=1,322 \[63%\]), alimentary tract and metabolism agents (n=1,034 \[49%\]), nervous system agents (n=966 \[47%\]), respiratory agents (n=803 \[38%\]), blood and blood-forming agents (n=632 \[30%\]), and general anti-infective agents for systemic use (n=435 \[21%\]) ([Table 2](#t2-tcrm-10-189){ref-type="table"}). Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, followed by diuretics, were the most common cardiovascular agents used. Proton-pump inhibitors, oral diabetes agents, and histamine-receptor blockers accounted for over half the use of alimentary tract and metabolism agents. Antidepressants were the most commonly used class of nervous system agents, and inhaled agents accounted for over 90% of respiratory agents.

Medication use during follow-up
-------------------------------

The number of subjects with polypharmacy increased from 949 (45%) at baseline to 1,559 (74%) in the 90-day period following the episode of CAP. The prevalence of poly-pharmacy remained stable throughout the remainder of the follow-up period, with 73% of patients remaining on five or more medications at the end of 1 year ([Figure 1](#f1-tcrm-10-189){ref-type="fig"}). Even when antibiotic use was excluded, the prevalence of polypharmacy remained similar: 42% at baseline, 70% within 90 days, and 72% at study end. Using a cutoff point of seven or more medications (23% baseline, 56% 90 days, 57% 365 days) or ten or more medications (5% baseline, 36% 90 days, 39% 365 days) indicated that the prevalence of polypharmacy increased even with more stringent definitions. We did not observe any absolute differences of 10% or greater in the prevalence of polypharmacy between the various age-groups ([Figure 1](#f1-tcrm-10-189){ref-type="fig"}).

Overall, the use of the most prevalent medication classes remained stable over time ([Table 2](#t2-tcrm-10-189){ref-type="table"} and [Figure 2](#f2-tcrm-10-189){ref-type="fig"}). As expected, the use of antibiotics increased substantially following discharge (33% absolute increase, *P*\<0.001) compared to the 1 week prior to presentation. Of the 1,142 subjects that had been dispensed an anti-infective agent between 0 and 90 days post-discharge, 34% were prescribed beta-lactams (penicillins, cephalosporins, carbapenems, etc), 20% macrolides, and 72% quinolones (not mutually exclusive). We considered that "any" antibiotic use within 90 days of pneumonia was related to the index episode of pneumonia. But antibiotic use remained elevated after 90-days over the course of follow-up, and in particular we noted increased new (ie, non-index event pneumonia-related) antibiotic use between 3 months and 1 year ([Figure 3](#f3-tcrm-10-189){ref-type="fig"}). Postpneumonia, the most common antibiotics prescribed were quinolones (13%), followed by beta-lactams (8%) and macrolides (6%).

New starts and stops of medications
-----------------------------------

The mean number of new medications started in the first 90 days of follow-up was 3.3 medications (SD 2.7). There were 1,690 (80%) patients who started at least one new medication class that they did not report receiving at baseline. The most common medication classes started over the 1 year postdischarge period were anti-infective agents, musculoskeletal agents, dermatological agents, nervous system agents, systematic hormones, alimentary tract and metabolism agents, and respiratory agents, in order of prevalence. In contrast, the mean number of medications discontinued was 2.4 (SD=2.6) in the first 90 days of follow-up. There were 1,553 patients (74%) who stopped at least one medication, and the most common medication classes to be stopped were alimentary tract and metabolism agents, nervous system agents, blood and blood-forming agents, and cardiovascular agents. The mean number of new starts and stops decreased to less than one medication per person after 90 days of follow-up and remained constant thereafter.

Discussion
==========

We found that in the first 90 days after an episode of CAP, the prevalence of polypharmacy within our cohort increased from 45% to 74%, and remained above 70% for up to 365 days, irrespective of antibiotic use. Although the prevalence of medication classes remained stable during the 1-year follow-up period, it was common for new medication starts and stops to occur within each class, especially within the immediate transition-of-care period (ie, within the first 3 months of follow-up). Interestingly, after completing an antibiotic course that was plausibly connected to the initial episode of pneumonia, fully a quarter of patients were using another anti-infective agent within 1 year.

Others have reported increases in the average number of medications and prevalence of polypharmacy in older adults following admission to an acute care hospital for any reason in the range of 48%--62%.[@b13-tcrm-10-189],[@b19-tcrm-10-189] To our knowledge, this is the first study reporting the prevalence of polypharmacy over time in a cohort of older adults, all of whom presented to medical attention with a single condition. We found nearly 75% of patients used five or more prescription medications following CAP, which is consistent with other studies that have measured polypharmacy rates in sicker populations, such as those living in a nursing home[@b13-tcrm-10-189],[@b16-tcrm-10-189],[@b19-tcrm-10-189] or those with diabetes.[@b15-tcrm-10-189] We found the use of cardiovascular, alimentary and metabolic, nervous system, and respiratory medications was relatively stable throughout follow-up, and the high prevalence of these medications is consistent with previous studies and reports.[@b13-tcrm-10-189],[@b17-tcrm-10-189],[@b19-tcrm-10-189],[@b29-tcrm-10-189]

Important changes in medication use were observed in the months following discharge, with both new medication starts and stops being most prevalent in the initial 90-day follow-up period and declining thereafter. The time frame immediately following discharge appears critical, particularly in older adults with multiple medications, where the transfer of care, resolution of acute illness, new medications, and challenges with adherence may combine to produce a higher risk of medication-related problems.[@b13-tcrm-10-189],[@b17-tcrm-10-189],[@b19-tcrm-10-189],[@b30-tcrm-10-189] However, we also observed new medications starts in over a quarter of the population and medication discontinuations in over 10% of the population up to 1 year following their initial CAP episode. The ongoing increase from baseline in the use of antibiotics is particularly remarkable. Although consistent with previous reports,[@b31-tcrm-10-189],[@b32-tcrm-10-189] an annual course of antibiotics in a quarter of the population has important implications with respect to community-wide resistance patterns and potential need for better antibiotic stewardship.[@b32-tcrm-10-189]

There are several limitations of our study. First, the measure of medication use in the week prior to their episode of CAP was based on patient self-report of medications (collected and verified by trained nurses in consultation with patients, proxies, pharmacies, medical records, and medical offices to capture current medication use accurately), whereas medication use during follow-up was measured using dispensing records from administrative data. However, in prior studies from this jurisdiction, self-report of cardiovascular, diabetes, and osteoporosis-related medications has been 90%--100% accurate when using the dispensing pharmacy as the reference standard.[@b33-tcrm-10-189],[@b34-tcrm-10-189] Moreover, given that medication use for several chronic disease medication classes (ie, cardiovascular and respiratory medications) did not substantially change and in fact was higher at baseline suggests that recall was not an issue.

Second, the administrative database does not capture over-the-counter medications, such as aspirin or lower-dose histamine-2 blockers, and our data likely underestimate the total number of medications being used. Third, due to the absence of information on the instructions for use, we were unable to quantify more thorough measures of medication burden, such as the medication regimen-complexity index,[@b35-tcrm-10-189] and could not assess medication appropriateness. It follows that not all polypharmacy is inappropriate; however, it is important to assess the medication regimen rigorously and ensure each medication has an appropriate indication, and is efficacious and safe for the patient.

In summary, we found that 80% of patients started and 74% of patients stopped at least one medication class within the first 90 days of their CAP episode, and 75% of older patients were subject to polypharmacy. This dynamic nature of medication use is particularly worrisome in older individuals who are more prone to adverse drug events, and our findings imply that the postdischarge or convalescent phase of pneumonia in older adults should lead to a thorough medication review with a goal to optimizing and rationalizing drug use while attempting to reduce unnecessary medications.
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###### 

Cohort characteristics of 2,105 subjects over age 65 years with community-acquired pneumonia who were hospitalized or presented to the emergency room

  Characteristics                                       
  --------------------------------------------- ------- -----
  Age, years, mean, SD                          78      8
   65--74 years, n                              784     37%
   75--85 years, n                              886     42%
   85 years and older, n                        435     21%
  Females, n                                    1,060   50%
  Previous comorbidities, n                             
   Cerebrovascular disease                      278     13%
   Heart disease                                1,069   51%
   Neoplasm                                     251     12%
   Renal disease                                205     10%
   COPD                                         642     30%
   Mental illness                               278     13%
  Pneumonia severity index, n                           
   Class I and II                               269     13%
   Class III                                    619     29%
   Class IV                                     932     44%
   Class V                                      285     14%
  Premorbid functional status, n                        
   Independent mobility                         1,918   91%
   Wheelchair/prosthesis                        122     6%
   Bedridden                                    65      3%
  Smoking status, n                                     
   Nonsmokers                                   1,169   56%
   Former smoker                                631     30%
   Current smokers                              305     14%
  Nursing home residents, n                     310     15%
  Number of medications at baseline, mean, SD   4.5     2.8
  Five or more medications, n                   949     45%

**Abbreviations:** SD, standard deviation; COPD, chronic obstructive pulmonary disease.

###### 

Prevalence of drug classes and number of medications utilized by 2,105 subjects over age 65 years with community-acquired pneumonia discharged from hospital or the emergency department

  Anatomical therapeutic chemical class                          Baseline, n   0--90 days' follow-up, n   91--180 days' follow-up, n   181--270 days' follow-up, n   271--365 days' follow-up, n                                       
  -------------------------------------------------------------- ------------- -------------------------- ---------------------------- ----------------------------- ----------------------------- ----- ----------- ----- ----------- -----
  Cardiovascular system                                          1,322         63%                        1,253                        60%                           1,217                         58%   1,211       58%   1,218       58%
   Renin--angiotensin system agents                              499           24%                        739                          35%                           734                           35%   742         35%   757         36%
   Beta-blockers                                                 225           11%                        330                          16%                           319                           15%   314         15%   340         16%
   Calcium-channel blockers                                      146           7%                         371                          18%                           359                           17%   365         17%   367         17%
   Diuretics                                                     625           30%                        700                          33%                           619                           29%   633         30%   636         30%
   Nitrates                                                      187           9%                         213                          10%                           203                           10%   199         9%    208         10%
   Lipid-lowering agents                                         276           13%                        317                          15%                           322                           15%   323         15%   350         17%
  Alimentary tract and metabolism                                1,034         49%                        924                          44%                           848                           40%   851         40%   849         40%
   Proton-pump inhibitors                                        314           15%                        438                          21%                           427                           20%   429         20%   446         21%
   H~2~-receptor blockers                                        88            4%                         88                           4%                            72                            3%    77          4%    65          3%
   Oral diabetes agents                                          261           12%                        229                          11%                           230                           11%   224         11%   224         11%
  Nervous system                                                 996           47%                        935                          44%                           872                           41%   843         40%   876         42%
   Antipsychotics                                                47            2%                         76                           4%                            72                            3%    66          3%    76          4%
   Antidepressants                                               328           16%                        358                          17%                           350                           17%   332         16%   351         17%
   Anxiolytics                                                   193           9%                         304                          14%                           280                           13%   266         13%   272         13%
   Hypnotics/sedatives                                           241           11%                        289                          14%                           252                           12%   267         13%   265         13%
  Respiratory system                                             803           38%                        859                          41%                           697                           33%   688         33%   660         31%
   Inhaled                                                       732           35%                        721                          34%                           656                           31%   642         30%   607         29%
  Blood and blood-forming organs                                 632           30%                        368                          17%                           341                           16%   370         18%   375         18%
  General anti-infectives for systemic use                       435           21%                        1,142                        54%                           500                           24%   491         23%   534         25%
  Systematic hormonal preparations, excluding sex hormones       397           19%                        593                          28%                           490                           23%   480         23%   500         24%
  Musculoskeletal system                                         359           17%                        524                          25%                           486                           23%   496         24%   502         24%
   NSAIDs                                                        351           17%                        293                          14%                           252                           12%   249         12%   240         11%
  Genitourinary system and sex hormones                          124           6%                         285                          14%                           263                           12%   278         13%   257         12%
  Dermatologicals                                                98            5%                         193                          9%                            228                           11%   219         10%   217         10%
  Immunomodulating agents                                        13            1%                         21                           1%                            20                            1%    19          1%    18          1%
  Mean number (SD) of medications                                4.5 (2.8)                                6.8 (4.0)                                                  6.3 (3.8)                           6.4 (3.9)         6.6 (4.0)   
  Subjects with polypharmacy (five or more unique medications)   949           45%                        1,559                        74%                           1,502                         71%   1,519       72%   1,540       73%

**Abbreviations:** NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation.
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